Actavis hit with IP suit over prostate cancer drug

06-12-2016

Astellas Pharma, Medivation and the regents of the University of California have collectively sued Actavis for alleged patent infringement over Xtandi (enzalutamide), a treatment for prostate cancer.


Actavis, Astellas, Medivation, Prostate Therapeutics, The Regents of the University of California, Xtandi, ANDA

LSIPR